Lexaria Bioscience Corp. LEXX
4.49 USD 0.00 (+0.00%)
Regular-session close
4.21 -0.28 -6.24%
Pre-market · Nov 20, 8:15 AM ET
4.17 Day range 4.49
2.43 52-week range 21.60
- YTD
- -51.51%
- 1 year
- -72.79%
News
benzinga.com Lexaria Bioscience Completes Final Dosing On Schedule With Human Pilot Study 7, GLP-1-H26-7, To Evaluate Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy Over Five Weeks Final visits were completed this week by all Study participants within all Study arms. With dosing complete and final blood samples taken, the Study work will now shift to laboratory sample analyses,…
thenewswire.com Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled Kelowna, BC – November 19, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that final dosing has been…benzinga.com Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical…
benzinga.com Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with
